Table 3.
Susceptibility profiles of HUMC strains. Isolates were designated susceptible (S), intermediate (I), or resistant (R) according to CLSI antibiotic breakpoint guidelines. Minimum inhibitory concentrations (MIC) were shown in brackets.
| Antibiotic/Isolate | A/S | AK | CAZ | CP | CPE | GM | IMP | LVX | MER | T/S | TE | TIM | TO | CST | TGC |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HUMC-1 | I (16/8) | S (≤16) | R (>32) | R (>2) | R (>16) | R (>8) | R (>8) | R (>4) | R (>8) | R (>2/38) | I (8) | R (>64) | R (>8) | S (≤2) | S (≤1) |
| HUMC-3 | R (>16/8) | R (>32) | R (>16) | R (>2) | R (>16) | R (>8) | R (>8) | R (>4) | R (>8) | R (>2/38) | I (8) | R (>64) | R (>8) | S (≤2) | R (4) |
| HUMC-4 | I (16/8) | S (≤16) | R (>16) | R (>2) | R (>16) | R (>8) | R (>8) | R (>4) | R (>8) | R (>2/38) | I (8) | R (>64) | S (≤4) | S (≤2) | I (2) |
| HUMC-5 | R (>16/8) | R (>32) | R (>16) | R (>2) | R (>16) | R (>8) | S (≤4) | R (>4) | I (8) | R (>2/38) | R (>8) | R (>64) | R (>8) | S (≤2) | S (≤1) |
| HUMC-6 | R (>16/8) | R (>32) | R (>16) | R (>2) | R (>16) | R (>8) | S (≤4) | R (>4) | I (8) | R (>2/38) | R (>8) | R (>64) | R (>8) | S (≤2) | S (≤1) |
| HUMC-9 | S (≤8/4) | S (≤16) | R (>16) | R (>2) | R (>16) | R (>8) | I (8) | R (>4) | R (>8) | R (>2/38) | I (8) | R (>64) | R (>8) | S (≤2) | I (2) |
| HUMC-10 | S (≤8/4) | R (>32) | R (>16) | R (>2) | R (>16) | R (>8) | S (≤4) | R (>4) | S (≤4) | R (>2/38) | R (>8) | R (>64) | R (>8) | S (≤2) | S (≤1) |
| HUMC-11 | R (>16/8) | R (>32) | R (>16) | R (>2) | I (16) | R (>8) | S (≤4) | R (>4) | I (8) | R (>2/38) | R (>8) | R (>64) | R (>8) | S (≤2) | S (≤1) |
| HUMC-12 | R (>16/8) | R (>32) | R (>16) | R (>2) | R (>16) | R (>8) | S (≤4) | R (>4) | S (≤4) | R (>2/38) | R (>8) | R (>64) | R (>8) | S (≤2) | S (≤1) |
| HUMC-13 | R (>16/8) | R (>32) | R (>16) | R (>2) | R (>16) | R (>8) | S (≤4) | R (>4) | I (8) | R (>2/38) | R (>8) | R (>64) | R (>8) | S (≤2) | S (≤1) |
| HUMC-14 | R (>16/8) | R (>32) | R (>16) | R (>2) | R (>16) | R (>8) | S (≤4) | R (>4) | I (8) | R (>2/38) | R (>8) | R (>64) | R (>8) | S (≤2) | S (≤1) |
| HUMC-15 | I (16/8) | R (>32) | R (>16) | R (>2) | R (>16) | R (>8) | R (>8) | R (>4) | R (>8) | R (>2/38) | I (8) | R (>64) | R (>8) | S (≤2) | R (4) |
| HUMC-16 | I (16/8) | R (>32) | R (>16) | R (>2) | R (>16) | R (>8) | R (>8) | R (>4) | R (>8) | S (≤2/38) | I (8) | R (>64) | R (>8) | S (≤2) | S (≤1) |
| HUMC-17 | I (16/8) | R (>32) | R (>16) | R (>2) | R (>16) | R (>8) | R (>8) | R (>4) | R (>8) | R (>2/38) | R (>8) | R (>64) | R (>8) | S (≤2) | S (≤1) |
| HUMC-18 | I (16/8) | R (>32) | R (>16) | R (>2) | R (>16) | R (>8) | R (>8) | R (>4) | R (>8) | R (>2/38) | I (8) | R (>64) | R (>8) | S (≤2) | I (2) |
| HUMC-19 | S (≤8/4) | R (>32) | R (>16) | R (>2) | R (>16) | R (>8) | R (>8) | R (>4) | R (>8) | R (>2/38) | R (>8) | R (>64) | R (>8) | S (≤2) | S (≤1) |
| HUMC-20 | I (16/8) | R (>32) | R (>16) | R (>2) | R (>16) | R (>8) | R (>8) | R (>4) | R (>8) | R (>2/38) | R (>8) | R (>64) | R (>8) | S (≤2) | S (≤1) |
| HUMC-21 | I (16/8) | R (>32) | R (>16) | R (>2) | R (>16) | R (>8) | R (>8) | R (>4) | R (>8) | R (>2/38) | R (>8) | R (>64) | R (>8) | R (>2) | S (≤1) |
| HUMC-22 | I (16/8) | R (>32) | R (>16) | R (>2) | R (>16) | R (>8) | R (>8) | R (>4) | R (>8) | R (>2/38) | I (8) | R (>64) | R (>8) | S (≤2) | S (≤1) |
| HUMC-23 | S (≤8/4) | R (>32) | R (>16) | R (>2) | R (>16) | R (>8) | R (>8) | R (>4) | R (>8) | R (>2/38) | R (>8) | R (>64) | R (>8) | S (≤2) | S (≤1) |
| HUMC-24 | R (>16/8) | R (>32) | R (>16) | R (>2) | I (16) | R (>8) | S (≤4) | R (>4) | I (8) | R (>2/38) | R (>8) | R (>64) | R (>8) | S (≤2) | S (≤1) |
Abbreviations: A/S, Ampicillin/Sulbactam; AK, Amikacin; CAZ, Ceftazidime; CP, Ciprofloxacin; CPE, Cefepime; GM, Gentamicin; IMP, Imipenem; LVX, Levofloxacin; MER, Meropenem; T/S, Trimethoprim/Sulfamethoxazole; TE, Tetracycline; TIM, Ticarcillin/K Clavulanate; TO, Tobramycin; CST, Colistin; TGC, Tigecycline.